Clinical systematic observation of Kangxin capsule curing vascular dementia of senile kidney deficiency and blood stagnation type

ObjectiveTo observe the validity and safety of Kangxin capsule curing the patients with vascular dementia (VaD).Patients and methodsFifty-six patients with vascular dementia of kidney deficiency and blood stagnation type were selected on the basis of defined diagnostic criteria and were randomly divided into Kangxin group (29) and control group (27), observing the relevant accumulation scores in dementia scale before and after treatment and changes of endothelin (ET), sex hormone, immunity and routine examinations.ResultsKangxin capsule can effectively improve the symptom of patients with VaD of senile kidney deficiency and blood stagnation type, and the average value of curative effect index of 29 patients in the treatment group is 23.01 ≥ 20%, i.e. effective; compared with that before treatment, both CD4 and CD4·CD8−1 rises (P < 0.05) after the treatment with Kangxin capsule; for the male VaD patients of the Kangxin group, T level increases (P < 0.05) and estrodial (E2)·testerone (T)−1 value decreases (P < 0.05) after the treatment; for the female VaD patients of the Kangxin group, E2, E2·T−1 value increases a great deal (P < 0.05) compared with that before treatment; ET level of both groups decreased on average (P < 0.01), and did not demonstrate any obvious toxic side effect.ConclusionsKangxin capsule is a valid and safe preparation of Chinese traditional medicine for curing VaD of senile kidney deficiency and blood stagnation type.